05/09/2024
Ocuphire Pharma announced it has dosed the first patient in its VEGA-3, phase 3 clinical trial (NCT06542497) of phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.
The company noted in a press release1 that phentolamine ophthalmic solution 0.75% is being developed to provide a non-invasive, convenient alternative to traditional corrective measures for presbyopia.
The trial is evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.
